RHYTHM PHARMACEUTICALS INC. - COMMON STOCK

Rhythm Pharmaceuticals to Report Third Quarter 2023 Financial Results on Tuesday, November 7, 2023

25 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Presents Data from its Long-term Extension Study of Setmelanotide Showing Sustained and Deepened BMI Reduction in Patients with Hypothalamic Obesity at One Year at ObesityWeek® 2023

17 Oct 2023 15:01:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

13 Oct 2023 15:01:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces Six Abstracts to be Presented at The Obesity Society’s Annual Meeting at ObesityWeek ®

10 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Presents New Data at ESPE 2023

22 Sep 2023 07:00:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Receives Orphan Drug Designation from European Medicines Agency for Setmelanotide for Treatment of Acquired Hypothalamic Obesity

19 Sep 2023 07:01:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

08 Sep 2023 15:01:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces Update to September Conference Participation

08 Sep 2023 06:59:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces New ICD-10 Diagnosis Code Established for Bardet-Biedl Syndrome

06 Sep 2023 06:59:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals to Present at Investor Conferences in September

28 Aug 2023 07:00:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces Pre-Marketing Early Access Authorization for Setmelanotide for Use in Patients with Hypothalamic Obesity in France

07 Aug 2023 07:00:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

04 Aug 2023 15:01:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Reports Second Quarter 2023 Financial Results and Business Update

01 Aug 2023 06:00:01 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces Two Publications Detailing Burden of Hyperphagia and Obesity on Patients and Caregivers Living with Bardet-Biedl Syndrome

19 Jul 2023 07:00:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals to Report Second Quarter 2023 Financial Results on Tuesday, August 1, 2023

17 Jul 2023 05:00:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

13 Jul 2023 15:01:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Presents Data Demonstrating BMI Reduction in Patients with Hypothalamic Obesity Treated with Setmelanotide over Six Months at ENDO 2023

17 Jun 2023 13:01:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals to Present at Goldman Sachs 44th Annual Global Healthcare Conference

07 Jun 2023 07:00:01 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

06 Jun 2023 15:01:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals and Genpharm Announce Collaboration to Provide IMCIVREE® (setmelanotide) to Patients in Gulf Cooperation Council Countries

22 May 2023 07:00:00 By Nasdaq GlobeNewswire